Kvika banki hf.
On 23 February 2021 Kvika banki hf. ("Kvika") disclosed that Kvika, TM hf. ("TM") and Lykill fjármögnun hf. ("Lykill") had signed a merger plan for the companies. On 26 February 2021 it was further disclosed that two out of four provisos in the merger agreement of the companies from 25 November 2020 had been satisfied. Remaining provisos being the approval of the Financial Supervisory Authority of the Central Bank of Iceland ("FME") for the merger and approval of the companies’ shareholders.
Today, 9 March 2021, FME notified Kvika, TM and Lykill that the Financial Supervision Committee had discussed the application for approval of the companies’ merger. It is the conclusion of the Committee that the merger will be approved provided that the merger process will be completed in accordance with provisions of the Act on Public Limited Companies.
Shareholders’ meetings will be held in each of Kvika, TM and Lykill on 30 March 2021, where the merger of the companies is on the agenda, cf. meeting notifications published on 8 March 2021.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ONWARD Medical NV18.9.2025 07:30:00 CEST | Press release
Concurrent Publications in Nature and Nature Medicine Highlight Advances in Blood Pressure Regulation after Spinal Cord Injury Using ONWARD ARC-IM Therapy
Sampo plc18.9.2025 07:30:00 CEST | Press release
Sampo plc’s share buybacks 17 September 2025
Biotalys NV18.9.2025 07:00:00 CEST | Press release
Biotalys Reports Half-Year 2025 Financial Results and Business Highlights
F. Hoffmann-La Roche Ltd18.9.2025 07:00:00 CEST | Press release
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
Ascom Holding AG18.9.2025 06:30:00 CEST | Press release
Michael Reitermann takes over the operational leadership of the Ascom Group as Delegate of the Board of Directors and interim CEO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom